The most successful chemotherapeutic, bevacizumab, is effective in 50% of NF2-SWN patients and has significant side effects.64 While MMP9 represents an attractive therapeutic target, direct inhibitors of MMP9 have met with failures in cancer clinical trials35 likely due to MMP9’s pleotropic role in physiologic processes. Here, NF2 is linked to cancer.